Humanigen Inc. (HGEN) – Company Press Releases
-
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
-
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
-
Humanigen Reports Third Quarter 2022 Financial Results
-
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
-
Humanigen Announces Retention of SC&H Capital as Financial Advisor
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm
-
Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm
-
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Humanigen, and Kohl’s and Encourages Investors to Contact the Firm
-
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
-
Humanigen Reports Second Quarter 2022 Financial Results
-
Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space
-
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
-
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
-
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
-
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
-
NIH/NIAID Locks ACTIV-5/BET-B Database
-
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
-
Humanigen Announces Participation and Presentation at Multiple Conferences in June
-
Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
-
Humanigen Reports First Quarter 2022 Financial Results
-
Humanigen Announces Participation and Presentation at Multiple Conferences in May
-
GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia
-
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
-
Humanigen Reports Year-End 2021 Financial Results
-
Humanigen to Present and Participate at Multiple Investor Events in March
-
Humanigen to Present at BIO CEO & Investor Conference
-
Humanigen Launches Managed Access Program for Lenzilumab
-
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
-
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
-
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
-
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
-
Humanigen to Present at Investor Conferences January 7 and 13, 2022
-
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
-
Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
-
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
-
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
-
Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
-
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
-
Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
-
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
-
Humanigen Announces Release of Abstracts at ASH
Back to HGEN Stock Lookup
